title: Access to innovative oncology medicines in Europe.
authors.affiliation: Department of Medical Clinic II, University Hospital, Frankfurt l.bergmann@em.uni-frankfurt.de.
authors.forename: L
authors.initials: L
authors.lastname: Bergmann
authors.affiliation: Federal Institute for Drugs and Medical Devices (BfArM), Bonn, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Enzmann
authors.affiliation: NDA Advisory Services Ltd, Prime House, Leatherhead, Surrey, UK.
authors.forename: S
authors.initials: S
authors.lastname: Thirstrup
authors.affiliation: Law Office, Cologne, Germany.
authors.forename: J K
authors.initials: JK
authors.lastname: Schweim
authors.affiliation: Pfizer Business Unit Oncology Europe/Africa/Middle East, Brussels, Belgium.
authors.forename: I
authors.initials: I
authors.lastname: Widera
authors.affiliation: Department of Internal Medicine, University Hospital, Innsbruck, Austria.
authors.forename: H
authors.initials: H
authors.lastname: Zwierzina
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D013673:Technology Assessment, Biomedical
chemical_list: D000970:Antineoplastic Agents